Merck Nixes study on prostate cancer where Keytruda therapy disappoints

Published Date: 02 Mar 2023

Merck & Co has halted late-stage trials of the combination with cancer drug Keytruda because preliminary data showed it was unlikely to achieve its primary goal.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

2.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

3.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

4.

Ketamine plus psychotherapy for "excellent" PTSD

5.

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot